Angiolo Gadducci
#165,040
Most Influential Person Now
Researcher
Angiolo Gadducci's AcademicInfluence.com Rankings
Angiolo Gadduccicomputer-science Degrees
Computer Science
#9826
World Rank
#10308
Historical Rank
Software Engineering
#267
World Rank
#272
Historical Rank
Database
#6779
World Rank
#7018
Historical Rank
Download Badge
Computer Science
Angiolo Gadducci's Degrees
- PhD Computer Science University of Florence
- Masters Computer Science University of Florence
- Bachelors Computer Science University of Florence
Similar Degrees You Can Earn
Why Is Angiolo Gadducci Influential?
(Suggest an Edit or Addition)Angiolo Gadducci's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The management of patients with uterine sarcoma: a debated clinical challenge. (2008) (242)
- Uterine leiomyosarcoma: analysis of treatment failures and survival. (1996) (229)
- Patterns of recurrence in patients with squamous cell carcinoma of the vulva (2000) (209)
- Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. (1995) (207)
- Serum tumor markers in the management of ovarian, endometrial and cervical cancer. (2004) (182)
- Endometrial stromal sarcoma: analysis of treatment failures and survival. (1996) (177)
- p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. (1997) (165)
- Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature (2011) (156)
- The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. (2008) (141)
- Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. (2000) (134)
- Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. (2000) (119)
- Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature (2006) (118)
- Management of borderline ovarian tumors: results of an Italian multicenter study. (2006) (116)
- Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. (1997) (113)
- Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary (2013) (109)
- Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. (1998) (109)
- Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. (2006) (108)
- Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. (2009) (105)
- Polycystic ovary syndrome and gynecological cancers: Is there a link? (2005) (100)
- Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. (2001) (97)
- The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. (1992) (93)
- Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors: A MITO-9 Retrospective Study (2011) (92)
- Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. (1995) (92)
- Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. (2017) (90)
- Treatment options in recurrent cervical cancer (Review). (2010) (90)
- Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. (1998) (89)
- An analysis of approaches to the management of endometrial cancer in North America: a CTF study. (1998) (88)
- High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. (1996) (87)
- An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. (2000) (87)
- Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. (2003) (86)
- Extra-Nuclear Signaling of Progesterone Receptor to Breast Cancer Cell Movement and Invasion through the Actin Cytoskeleton (2008) (83)
- Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. (2009) (83)
- Tissue biomarkers as prognostic variables of cervical cancer. (2013) (82)
- Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. (2012) (79)
- Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. (2002) (77)
- Ovarian metastases in early‐stage cervical cancer (IA2–IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study) (2007) (77)
- Prospective multicenter study on CA 125 in postmenopausal pelvic masses. (1994) (76)
- Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. (2003) (76)
- Surveillance of patients after initial treatment of ovarian cancer. (2009) (75)
- Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric Study (2009) (72)
- Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. (2014) (71)
- Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. (2016) (70)
- Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. (2004) (70)
- Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). (2010) (70)
- Weekly epirubicin in the treatment of gestational breast cancer (GBC) (2009) (70)
- Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. (2001) (69)
- Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS) (2017) (69)
- Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. (1999) (68)
- Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study (2003) (68)
- The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. (2002) (67)
- Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status (2019) (67)
- An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. (1995) (66)
- Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. (2006) (66)
- Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. (1996) (66)
- Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. (2009) (64)
- Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer (2007) (64)
- Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. (2007) (62)
- Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. (1996) (62)
- Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. (1994) (62)
- The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. (2004) (61)
- Hormone replacement therapy and cancer (2001) (60)
- Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. (2005) (60)
- Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. (2001) (60)
- Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. (2015) (59)
- Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. (1991) (59)
- Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. (1994) (58)
- The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. (2003) (57)
- Surveillance Procedures for Patients Treated for Endometrial Cancer: A Review of the Literature (2010) (56)
- Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. (2005) (55)
- Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: an Italian multicenter retrospective study (CTF Study). (2013) (55)
- Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. (2019) (54)
- Ovarian function and childbearing issues in breast cancer survivors (2007) (53)
- The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study (2016) (52)
- Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. (2012) (52)
- Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research (2020) (51)
- Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. (1999) (51)
- Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. (2017) (49)
- Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. (1995) (49)
- The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option (2009) (49)
- Prognostic factors in uterine sarcoma. (2011) (49)
- Novel insights on the malignant transformation of endometriosis into ovarian carcinoma (2014) (48)
- Melanoma of the lower genital tract: Prognostic factors and treatment modalities. (2018) (47)
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. (2021) (46)
- Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. (1993) (45)
- P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. (2006) (45)
- Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer (2005) (45)
- Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues (1999) (44)
- The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer (2001) (44)
- Clear cell carcinoma of the endometrium: a biological and clinical enigma. (2010) (44)
- Molecular target therapies in endometrial cancer: From the basic research to the clinic (2008) (44)
- Comparison of the initial surgical experience with robotic and laparoscopic myomectomy (2014) (43)
- Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. (2002) (42)
- Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. (2014) (41)
- Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer (2016) (39)
- Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research (2014) (39)
- Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? (2015) (37)
- Surgical and Medical Treatment of Clear Cell Ovarian Cancer: Results From the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 Retrospective Study (2011) (37)
- The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study. (2010) (37)
- Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. (2019) (37)
- Serum markers as prognostic factors in epithelial ovarian cancer: an overview. (2000) (37)
- The Role of HE4 in Ovarian Cancer Follow-up: A Review (2014) (36)
- Up date in the management of advanced ovarian carcinoma. (1999) (35)
- Biochemical prognostic factors and risk of relapses in patients with cervical cancer. (2007) (35)
- Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy (2010) (34)
- The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. (2010) (34)
- Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. (2014) (34)
- Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. (2008) (34)
- Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer (2007) (33)
- Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. (2003) (33)
- Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. (1996) (32)
- Could Different Follow-Up Modalities Play a Role in the Diagnosis of Asymptomatic Endometrial Cancer Relapses?: An Italian Multicentric Retrospective Analysis (2012) (32)
- Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study (2016) (32)
- Uterine smooth muscle tumors of unknown malignant potential: A challenging question. (2019) (32)
- Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. (2003) (31)
- Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients (1997) (31)
- The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. (1992) (31)
- PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. (2017) (30)
- Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature (2007) (30)
- p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. (2000) (30)
- Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. (2003) (29)
- Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage Ib-II endometrial cancer: an Italian multicenter retrospective study (CTF study). (2014) (29)
- Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. (2011) (28)
- Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index (2017) (28)
- Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. (2000) (28)
- Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data (2004) (28)
- Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. (2015) (27)
- Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. (2010) (27)
- Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions (2007) (26)
- Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue (2009) (26)
- Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment (2016) (26)
- Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. (1994) (26)
- Current management of fallopian tube carcinoma (2002) (26)
- PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. (2016) (25)
- Adjuvant chemotherapy in early stage uterine sarcomas: an open question. (2001) (25)
- Preoperative serum E-cadherin assay in patients with ovarian carcinoma. (1999) (25)
- Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. (2011) (25)
- Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. (1993) (24)
- Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists. (2019) (23)
- Second-line treatment and consolidation therapies in advanced ovarian cancer (2001) (23)
- Discontinuation of modern hormonal contraceptives: an Italian survey (2016) (23)
- Fertility drug use and risk of ovarian tumors: a debated clinical challenge (2013) (23)
- Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. (2006) (22)
- An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens (2012) (22)
- Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study (2013) (22)
- Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. (2001) (21)
- Treatment options in patients with recurrent ovarian cancer. (2001) (21)
- First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. (2003) (21)
- Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. (2021) (21)
- Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. (1997) (20)
- Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. (2005) (20)
- LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2020) (20)
- Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours (2014) (20)
- Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit? (2016) (19)
- Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. (2001) (19)
- Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy (2013) (19)
- Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. (1998) (19)
- Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research (2020) (19)
- Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. (1996) (19)
- Alternatives to risk-reducing surgery for ovarian cancer. (2013) (18)
- Steroid hormones in endometrial and breast cancer. Review. (1997) (18)
- Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer. (1998) (18)
- Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy. (2013) (18)
- Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. (2007) (18)
- Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development (2018) (17)
- Serum interleukin-6 levels in uterine malignancies. Preliminary data. (1994) (17)
- Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study (2012) (17)
- The evolving role of adjuvant therapy in endometrial cancer. (2011) (17)
- A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. (1990) (17)
- Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis. (2017) (17)
- Gamma-glutamyltranspeptidase activity in human ovarian carcinoma. (1996) (16)
- Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. (1997) (16)
- Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2) (2009) (16)
- Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer (2017) (16)
- Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. (2004) (16)
- Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9) (2014) (15)
- Pretreatment Platelet and Hemoglobin Levels Are Neither Predictive Nor Prognostic Variables for Patients With Locally Advanced Cervical Cancer Treated With Neoadjuvant Chemotherapy and Radical Hysterectomy: A Retrospective Italian Study (2010) (15)
- Hormone replacement therapy and gynecological cancer. (1997) (15)
- Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia (2015) (15)
- Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer. (1997) (15)
- Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. (2016) (15)
- Reproductive Outcomes After Gestational Trophoblastic Neoplasia. A Comparison Between Single-Agent and Multiagent Chemotherapy: Retrospective Analysis From the MITO-9 Group (2017) (15)
- Ovarian cancer: optimal chemotherapy in relapsed disease. (2000) (14)
- Pharmacological treatment for uterine leiomyosarcomas (2015) (14)
- The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis (1992) (14)
- Relationship between interval from surgery to radiotherapy and local recurrence rate in patients with endometrioid-type endometrial cancer: a retrospective mono-institutional Italian study. (2012) (14)
- CARCINOSARCOMA OF THE UTERUS : A CLINICOPATHOLOGICAL MULTICENTER CTF STUDY (1998) (14)
- Surveillance Procedures for Patients With Cervical Carcinoma: A Review of the Literature (2009) (14)
- The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study. (1996) (14)
- Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature (2018) (13)
- Elevated serum levels of neopterin and soluble interleukin‐2 receptor in patients with ovarian cancer (1994) (13)
- Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study (2021) (13)
- The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO) (1994) (13)
- New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications (2012) (13)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (13)
- Renal impairment in patients with ovarian cancer. (2003) (13)
- Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer (1995) (13)
- The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow‐up of patients (1992) (13)
- DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis (2016) (12)
- Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer. (1996) (12)
- Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes (2017) (12)
- Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). (2020) (12)
- Endometrial Cancer: When Upfront Surgery Is Not an Option. (2020) (12)
- Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. (1996) (12)
- A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma. (1990) (12)
- Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study. (2016) (12)
- Factor VIIIR:Ag plasma levels in patients with cervical and ovarian carcinoma. (1988) (12)
- Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. (1987) (12)
- Evaluation of FHIT gene alterations in ovarian cancer. (1998) (11)
- Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists. (2020) (11)
- Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. (2016) (11)
- Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study (2014) (11)
- Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. (1997) (11)
- The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data. (1989) (11)
- Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option (2013) (11)
- Adenoid Cystic Carcinoma of Bartholin’s Gland: What Is the Best Approach? (2020) (11)
- Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. (2018) (11)
- Prognostic value of lymph node status and number of removed nodes in patients with squamous cell carcinoma of the vulva treated with modified radical vulvectomy and inguinal-femoral lymphadenectomy. (2012) (11)
- Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. (1991) (10)
- Endocrine therapy for gynecological cancer. (1999) (10)
- Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. (2010) (10)
- Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer. (2012) (10)
- Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study (2019) (10)
- Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma? (2020) (10)
- Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. (1995) (10)
- Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. (1993) (10)
- Surgery and radiotherapy in the treatment of early stage uterine sarcomas. (1989) (10)
- The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer. (1995) (10)
- The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. (1988) (10)
- Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix – An Italian Multicenter Retrospective Study (2018) (10)
- Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. (2005) (9)
- Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. (1994) (9)
- Recurrence patterns in patients with early stage cervical cancer treated with radical hysterectomy and external pelvic irradiation. (1995) (9)
- Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma? (2003) (9)
- Definitive radiotherapy for recurrent vulvar carcinoma after primary surgery: a two-institutional Italian experience (2019) (9)
- Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist (2020) (9)
- Times and sites of relapses after negative second look in advanced epithelial ovarian cancer. (1994) (9)
- The influence of some prognostic factors on the clinical outcome of patients with squamous cell carcinoma of the vulva. (1992) (9)
- Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study. (1999) (9)
- Analysis of treatment failures in patients with early-stage uterine leiomyosarcoma. (1995) (8)
- The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer (2021) (8)
- Pretreatment plasma levels of fibrinopeptide‐A (FPA), D‐dimer (DD), and von Willebrand Factor (vWF) in patients with operable cervical cancer: Influence of surgical‐pathological stage, tumor size, histologic type, and lymph node status (1994) (8)
- Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. (2015) (8)
- Neoadjuvant chemotherapy and concurrent chemoradiation in the treatment of advanced cervical cancer. (2001) (8)
- The assessment of the hemostasis system in patients with ovarian and cervical carcinoma (1991) (8)
- Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer. (2009) (8)
- Treatment planning in endometrial cancer (2003) (8)
- Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data. (1993) (8)
- Benign breast diseases, contraception and hormone replacement therapy. (2012) (8)
- The therapy of verrucous carcinoma of the vulva. Observations on three cases. (1989) (8)
- Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma : alone and in comparison with CA125 and SCC (1992) (7)
- Benign ovarian fibroma associated with free peritoneal fluid and elevated serum CA 125 levels. (1999) (7)
- Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research (2020) (7)
- The association of ovarian dysgerminoma and gonadoblastoma in a phenotypic female with 46 XY karyotype. (1994) (7)
- Perivascular epithelioid cell tumors (PEComa) of the female genital tract: A challenging question for gynaecologic oncologist and pathologist (2020) (7)
- Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. (2018) (7)
- The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC) (1994) (7)
- Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study (2020) (7)
- Monitoring of Hematoporphyrin Injected in Humans and Clinical Prospects of its Use in Gynecologic Oncology (1984) (7)
- Determination of serum levels of different cytokeratins in patients with uterine malignancies. (1994) (7)
- Preoperative evaluation of CA 125 and CA 19-9 serum levels in patients with ovarian masses. (1988) (7)
- Carcinoma developing in bladder exstrophy. Case report (1987) (7)
- Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review (2021) (6)
- Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study (2019) (6)
- Immunohistochemical detection of p185 product, p21 product, and proliferating cell nuclear antigen (PCNA) in formalin-fixed, paraffin-embedded tissues from ovarian carcinomas. Preliminary data. (1994) (6)
- Adjuvant Radiotherapy in High-Risk Squamous Cell Carcinoma of the Vulva: A Two-Institutional Italian Experience (2017) (6)
- Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM) (2020) (6)
- The management of malignant nondysgerminomatous ovarian germ cell tumors. (2003) (6)
- A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab (2019) (6)
- Percutaneous nephrostomy in patients with advanced or recurrent cervical cancer. (1994) (5)
- Epidoxorubicin (EPIDX), carboplatin (CBDCA) and paclitaxel (PTX) in advanced epithelial ovarian cancer (AEOC) (1997) (5)
- Dose Individualization Can Minimize Nephrotoxicity due to Carboplatin Therapy in Patients With Ovarian Cancer (2009) (5)
- Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO). (1992) (5)
- The topical administration of steroids in the treatment of typical vulvar dystrophies. (1989) (5)
- Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy (2019) (5)
- Prognostic factors affecting long-term survival of advanced ovarian cancer (AOC) patients (pts): univariate and multivariate analysis at 12 years follow-up (1995) (5)
- Comparison between single‐site and multiport robot‐assisted hysterectomy in obese patients with endometrial cancer: An Italian multi‐institutional study (2019) (5)
- Transrectal ultrasonography and cervical neoplasia. A preliminary report. (1984) (5)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial (2016) (5)
- MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach (2021) (4)
- The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer. (1998) (4)
- Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer” (2021) (4)
- PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic (2017) (4)
- Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer (2006) (4)
- Disease-free survival in patients with squamous cell carcinoma of the vulva treated with radical vulvectomy and bila¬teral inguinal -femoral lymphadenectomy: analysis of prognostic variables. (1993) (4)
- A phase II combination study of bortezomib with pegylated-liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens (2008) (4)
- The potential of primary cytoreductive surgery in patients with FIGO stages III and IV ovarian carcinoma. (1990) (4)
- Evaluation of some hemostatic parameters in patients with cervical carcinoma. (1990) (4)
- Analysis of the Evolution in the Management of Endometrial Cancer in Italy: A CTF Study (2002) (4)
- Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study (2022) (4)
- Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer. (2017) (4)
- The clinical, serological, pathological and immunocytochemical features of a case of primary carcinoma of the fallopian tube. (1993) (4)
- Evaluation of the central dopaminergic activity in gestational hyperprolactinaemia by means of the electroretinographic technique. (1985) (4)
- Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer. (1986) (4)
- Platinum compounds and paclitaxel in advanced epithelial ovarian cancer. (1997) (4)
- Ovarian cancer in elderly women (1997) (3)
- PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer. (2014) (3)
- An analysis of different approaches to ovarian cysts in Italy. (2004) (3)
- Post-traumatic Stress Disorder in patients with ovarian cancer (2017) (3)
- CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer. (1991) (3)
- Pelvic ultrasound, serum CA125 assay and serum CA72-4 assay in the differential diagnosis of ovarian masses. (1991) (3)
- Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy? (2016) (3)
- Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response (2021) (3)
- Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic (2007) (3)
- Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy (2021) (3)
- Angiosarcomaafteradjuvantradiotherapy in high-risksquamouscell carcinoma of the vulva: a case report (2019) (3)
- Clear cell endometrial cancer: a CTF multicentre Italian study. (2015) (3)
- Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes (2021) (2)
- Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study. (2016) (2)
- P 53 Gene Status in Patients with Advanced Serous Epithelial Ovarian Cancer in Relation to Response to Paclitaxel-plus Platinum-based Chemotherapy and Long-term Clinical Outcome (2008) (2)
- Prospective multicenter study on the clinical utility of ca-72.4 in postmenopausal patients with pelvic mass. (1995) (2)
- Immunoscintigraphy in ovarian cancer (1996) (2)
- Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab (2022) (2)
- Cisplatin and carboplatin in combination chemotherapy for advanced ovary cancer. (1989) (2)
- Second look laparotomy in the management of malignant epithelial ovarian neoplasias. (1986) (2)
- ‘Bat‐like’ choroid plexus and other sonographic features in trisomy 22 at the first trimester of pregnancy (2013) (2)
- Unilateral adnexal agenesis and dermoid cyst: fertility implications (2015) (2)
- P53 alterations are predictive of aggressiveness in ovarian carcinomas (1996) (2)
- Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research (2022) (2)
- Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. (2016) (2)
- Photodynamic therapy of gynecologic tumors (1986) (2)
- Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex (2021) (2)
- The role of the French-Italian glossary of complications in the outcome evaluation of cervical cancer treatment: an Italian multicentric study. (2003) (2)
- Adjuvant treatment of early stage ovarian carcinoma. (1990) (2)
- Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma. (1994) (2)
- Wertheim's radical hysterectomy with pelvic lymphadenectomy in the treatment of cervical carcinoma at the Obstetric and Gynecological Clinic of the University of Pisa. (1985) (2)
- Hemorrhagic uterine necrosis after surgical vessel ligation and B-Lynch suture in persistent post-cesarean uterine atony: case report and review of literature - (2016) (2)
- High dose versus standard doses of cisplatin (P) in combination with epidoxorubicin (E) and yclophosphamide (C) in advanced ovarian cancer (AOC) patients (pts) with bulky residual disease : a randomized trial (1993) (2)
- Tumor marker association in ovarian and cervical cancer. (1993) (1)
- Fluorescence detection and porphyrin-sensitized phototreatment of gynecologic tumors. (1985) (1)
- Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in patients with cervical cancer. (1996) (1)
- Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists (2022) (1)
- The combined evaluation of ultrasound, serum CA125 assay and serum CA19-9 assay in discriminating a benign from a malignant ovarian mass. (1990) (1)
- Cancer in pregnancy: Proposal of an italian multicenter study. gynecologic oncology group of the italian society of gynecology and obstetrics (sigo) (2018) (1)
- Prognostic factors in granulosa cell tumors (GCT) . A MITO-9 retrospective study (2011) (1)
- Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study (2020) (1)
- Impact of PET/CT with FDG on the clinical management of patients with ovarian cancer (2010) (1)
- Fertility outcome of breast cancer and Hodgkin’s lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists (2013) (1)
- The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study (2021) (1)
- Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study (2022) (1)
- Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer. (1992) (1)
- Diagnostic and therapeutic applications of porphyrins with visible light in gynecological oncology (1985) (1)
- Tumor markers of epithelial ovarian cancer: Role in diagnosis and therapy. (1999) (1)
- Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue (2020) (1)
- Reproductive variables, fertility drugs and epithelial ovarian tumor risk. (2004) (1)
- Uptake and clearance of hematoporphyrin administered to patients with gynecologic neoplasias: molecular mechanisms and clinical prospects (1983) (1)
- Prospective study on the clinical utility of CA 125 and CA 72-4 in preoperative diagnosis of postmenopausal patients with pelvic masses. (1995) (1)
- Liposome Encapsulated Doxorubicin Citrate (Ledc) as an AlternativeTherapeutic Option for Patients with Recurrent Ovarian Cancer Sufferingfrom Doxorubicin-Related Cutaneous Toxicity (2013) (1)
- Safety of using substitute hormonal therapy following oncological treatment of the malignant tumors of breast and female genital (1998) (1)
- Uterine papillary serous carcinoma. (2003) (1)
- Cisplatin-dose intensity in advanced ovarian carcinoma (1993) (1)
- Serum measur¬ments of CA125, CA19.9, CA15.3, and TAG-72 in patients with epithelial ovarian cancer. (1993) (1)
- p53 gene mutations predict chemoresistance in ovarian cancer. (1997) (1)
- Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study (2021) (1)
- The Minimally Invasive Approach for Endometrial Cancer: Robotic Versus Laparoscopic Hysterectomy and Pelvic Lymphadenectomy (2009) (1)
- Endometrial cancer: Analysis of treatment modality in Italy (1999) (1)
- Chemoprevention and endocrine therapy of endometrial carcinoma (2002) (1)
- Analysis of failures in patients with cervical carcinoma treated by radical surgery and external pelvic irradiation. (1988) (1)
- The role of intraperitoneal therapy in the treatment of epithelial ovarian cancer (1992) (1)
- 2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC) (2015) (1)
- Ovarian metastases in early-stage cervical cancer (IA2–IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study) (2006) (1)
- p53 nuclear accumulation in preneoplastic lesions and stage I uterine endometrioid adenocarcinoma. (1997) (1)
- Phototherapy of tumors sensitized by liposome-bound porphyrins locally infiltered in neoplastic areas (1984) (1)
- Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168]. (2020) (1)
- Struma ovarii. Observations on three cases. (1984) (1)
- Minimization of cisplatin nephrotoxicity in high-risk patients. (1996) (1)
- Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors. (1992) (1)
- The resistance to PARP inhibitors in epithelial ovarian cancer: State of art and perspectives of biological and clinical research (2021) (1)
- Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups (2022) (1)
- Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial (2021) (1)
- Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. (2006) (1)
- Melanoma: risks of non-reproductive cancer and relationship to hormone replacement therapy (2003) (0)
- [Comparison of serum determinations of CA125, CA15-3 and CA50 in the preoperative evaluation of adnexal tumors]. (1988) (0)
- Cervical Adenocarcinoma: A Still Under-investigated Malignancy (2022) (0)
- CA549, a new mucin-like cancer-associated antigen, in the diagnosis of ovarian carcinoma (1990) (0)
- Epidoxorubicin (Epidx), paclitaxel (TAX) and carboplatin (CBDCA) in advanced epithelial ovarian ancer (AEOC) (1999) (0)
- [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin]. (1988) (0)
- Serum CA125 and TAG-72 assays in the management of ovarian carcinoma (1993) (0)
- Comparison of common clinico-pathological prognostic variables and serum CA125 assay as predictors of clinical outcome in patients with advanced ovarian carcinoma (1993) (0)
- A narrative review of pregnancy after malignancies in young women that don't originate in the female genital organs or in the breast. (2021) (0)
- Prognostic relevance of preoperative levels of soluble receptors for TNF (55 kDa s-TNF-R and75 kDa s-TNF-R)in patients with advanced ovarian cancer. Preliminary data (1994) (0)
- Second-look laparotomy versus CA-125 assay in the evaluation of the status of disease in patients with ovarian carcinoma (1988) (0)
- CAM26 and CAM29 carci¬ noma-associated mucin epitopes in ovarian carcinoma: comparison with CA125. (1989) (0)
- Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma (2022) (0)
- Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian carcinoma with residual disease <2cm after second-look : preliminary report of a randomized study. (1993) (0)
- [Serum CA 125 and TPA determination in malignant neoplasms of the uterus]. (1988) (0)
- Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
- The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma. (1989) (0)
- Phototherapy of local recurrences of squamous cell carcinoma of the vulva (1989) (0)
- CAM26, CAM29, and mucin- like associated antigen in epithelial ovarian cancer. (1990) (0)
- Contents Vol. 40, 2017 (2017) (0)
- Renal involvement in patients with ovarian cancer: morphological alterations and functional impairment (2000) (0)
- Brenner's tumor. Observations on six cases. (1984) (0)
- New perspectives in the pharmacological treatment of cervical cancer: experimental and clinical researches (2007) (0)
- p53 and ovarian carcinoma. (1997) (0)
- Intensive follow-up program in patients with clinical stage I endometrial cancer (2000) (0)
- Serum antibodies against p53 in patients with epithelial ovarian cancer: relationship with response to chemotherapy (1997) (0)
- Tumor markers assay in the surveillance of ovarian carcinoma (1988) (0)
- Preliminary results on the use of Ca 15-3 in malignant ovarian pathology. (1987) (0)
- Incidence of malignant ovarian neoplasms in the provinces of Pisa, Lucca, Livorno and La Spezia during the period 1976-1981. (1982) (0)
- 750P Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity (2021) (0)
- The treatment of acute and late vaginal toxicity after adjuvant high dose rate [HDR] vaginal brachytherapy in patients with intermediate risk endometrial cancer: Is local therapy with hyaluronic acid of clinical benefit? (2017) (0)
- P53 overexpression in stage I of endomeitrial adenocarcinoma (1993) (0)
- Breast cancer in pregnancy: a real clinical challenge (2007) (0)
- Haemophilus vaginalis in PAP smears (1985) (0)
- Gynecologic malignancies and reproductive outcome (2003) (0)
- Pelvic ultrasound and serum markers in the diagnostic approach to epithelial ovarian cancer (1992) (0)
- Advanced ovarian cancer: does treatment have any impact on long- term survival? (1991) (0)
- Cytogenetic investigations of ovarian cancer: preliminary data. (1989) (0)
- Combination regimen including cisplatin, epirubicin, and cyclophosphamide (PEC) in advanced or recurrent endometrial cancer (1999) (0)
- High dose epidoxorubicin (EPIDX) and lonidamine (LND) in patients (PTS) with refractory or recurrent epithelial ovarian carcinoma (EOC) (1994) (0)
- Clinical management of uterine malignancies (2006) (0)
- Nephrotoxicity due to carboplatin therapy in ovarian cancer patients. (2008) (0)
- A comparison of several tumor markers in the diagnosis, monitoring and follow-up of patients with epithelial ovarian cancer (1989) (0)
- . Anticomplement and heparin-like activities in human placentas from term deliveries in women affected by diabetes mellitus (DM) and in woman affected by gestosis (EPH) (1982) (0)
- Recent progress in the treatment of ovarian cancer (1994) (0)
- Soluble interleukin-2 receptor (sIL-2R) levels in patients with cervical and endometrial carcinoma: preliminary data (1992) (0)
- Brenner's tumor (1984) (0)
- [Serum CA125, CA19-9 and TPA in the diagnostic approach to neoplastic pathology of the ovary]. (1987) (0)
- Prevention of cis-platinum nephrotoxicity in a high-risk patient. (1996) (0)
- The association of serum CA125 and CA72.4 in the monitoring of patients with epithelial ovarian cancer (1991) (0)
- Systemic chemotherapy in epithelial ovarian cancer: pro (2009) (0)
- CA 72-4, TATI, CA50, and CA-125 in uterine cancer (1988) (0)
- The treatment of uterine carcinosarcoma (2009) (0)
- Intraperitoneal versus systemic cisplatin (P) in combination with epidoxorubicin (E) and cytosan (C) as first line treatment in advanced ovarian cancer (AOC) patients with minimal residual disease after initial surgery: preliminary results of a prospective randomized trial (1993) (0)
- The serum assay of solu¬ ble CD44 standard (sCD44st), CD44 splice variant v5 (sCD44v5),and CD44 splice variant v6 (sCD44v6) in patients with advanced ovarian cancer (1997) (0)
- p53 expression in endometrial preneoplastic and neoplastic lesions (1997) (0)
- Breast cancer- does the choice of progesterone influence the risk of breast cancer? (2007) (0)
- Serum biomarkers in epithelial ovarian cancer. (2010) (0)
- Ovarian cancer: role of PET/CT with 18F-FDG on the clinical management of patients after primary treatment (2011) (0)
- Tumori borderline dell' ovaio (2002) (0)
- Longitudinal analysis of tumor markers in epithelial ovarian cancer (1995) (0)
- The role of some tumor antigens in the management of epithelial ovarian cancer (1989) (0)
- Human T elomerase R everse T ranscriptase m RNA E xpression Assessed b y R eal-Time R everse T ranscription P olymerase Chain R eaction P redicts C hemosensitivity i n P atients W ith Ovarian C arcinoma (2003) (0)
- Adjuvant treatment of stage I-II malignant mixed mesodermal tumors (MMMT) of the uterus: a multicenter CTF study (1996) (0)
- Cutaneous malignant melanoma: epidemiology, endocrine features and hormone replacement therapy (2002) (0)
- BORDERLINE OVARIAN TUMORS: MULTICENTER STUDY AND ANALYSIS OF the LITERATURE (2007) (0)
- SECOND-LINE TREATMENT OF PARTIALLY-PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A MANGO - PIEMONTE E VALLE D'AOSTA CANCER NETWORK ITALIAN MULTICENTRIC RETROSPECTIVE STUDY (2010) (0)
- Endometrial stromal sarcoma : analysis of a retrospective multicentric Italian study. (1995) (0)
- Intraperitoneal vs systemic chemotherapy for advanced ovarian cancer patients with minimal residual disease after initial surgery: prelimary results of a randomized study (1995) (0)
- Placental-like alkaline phosphatase (PLAP) in gynecological malignancies (1989) (0)
- Evaluation of the new immunoradiometric assay CA-195 in epithelial ovarian cancer : comparison with CA125, CA19-9, CA15-3, CA72-4 (1989) (0)
- [Analysis of failures in radiation and surgical treatment of endometrial carcinoma in FIGO stage I]. (1988) (0)
- Surgical technical problems in recurrent epithelial ovarian cancer (1999) (0)
- Multidrug resistance (MDR-1) expression in ovarian carcinoma (1997) (0)
- Primary carcinoma of the fallopian tube: A Multicenter CTF study (2000) (0)
- Polychemotherapy with carmustine, cyclophosphamide plus adriamycin in the treatment of advanced ovarian cancer. (1985) (0)
- FDG PET/CT in the clinical management of patients with ovarian cancer after primary treatment. (2012) (0)
- 852 Molecular landscape in high-grade serous ovarian cancer: the correlation between BRCA mutational status and stromal p16 expression (2021) (0)
- Biological parameters predictive of chemoresistance in ovarian cancer (1999) (0)
- Current status of preoperative and adjuvant irradiation in endometrial cancer: A CTF analysis in Western Europe (1996) (0)
- Clinical value of mucin tumor markers in epithelial ovarian cancer (1991) (0)
- Mucin-like carcinoma-associated antigen (MCA) and CA15-3 in ovarian carcinoma (1989) (0)
- Karyotype alterations in human ovarian cancer (1989) (0)
- Computed tomography (C.T.)in the follow-up of gynaecological neoplasias. (1985) (0)
- Subject Index, Vol. 13, 1992 (1992) (0)
- Serum Ca125 and other tumor markers in ovarian cancer. (2001) (0)
- A combination of CA125, CA19-9, CA15-3, CA50, CA72-4 and TATI in the monitoring of ovarian carcinoma (1989) (0)
- Pattern of recurrences in early stage uterine sarcoma: A retrospective CTF study (1999) (0)
- Synchronous adenoacanthoma of the ovary and endometrial adenocarcinoma. Report of two cases. (1986) (0)
- Primary Perivascular Epithelioid Cell Tumor (PEComa) of the Ovary: A Case Report and Review of the Literature (2021) (0)
- [Tumor markers: new prospects in the diagnosis and clinical monitoring of malignant epithelial neoplasms of the ovary]. (1985) (0)
- P53 overexpression in ovarian cancer: correlation with clinicopathological parameters and chemosensitivity (1995) (0)
- Current experience of hematoporphyrin-red light association in gynecologic oncology (1987) (0)
- Pattern of recurrence in endometrial cancer: A retrospective CTF study (1999) (0)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (0)
- Pregnancy-associated cancers: frequency and temporal trends in Italy (2019) (0)
- Stage I endometrial carcinoma: a comparison between two different therapeutic approaches. (1985) (0)
- Clinical behaviour of 208 stage II endometrial cancer cases (1999) (0)
- Pleiotropic drug resistance in epithelial ovarian cancer (1991) (0)
- Colposcopic, cytologic and histologic aspects of cervix uteri in adolescents. (1982) (0)
- Trabectidin: a new option for recurrent ovarian cancer (2011) (0)
- Risk of recurrences in patients with epithelial ovarian cancer: Analysis of two CTF studies (1997) (0)
- Prognostic role of immunosuppressive advanced ovarian cancer acidic protein in (1996) (0)
- Surgical cytoreduction and combination chemotherapy in the treatment of advanced epithelial ovarian cancer (1989) (0)
- Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the Clinical Outcome of Early-stage Endometrial Cancer Patients Treated With Adjuvant Vaginal Brachytherapy (2022) (0)
- Small doses of insulin for potential diabetes in pregnancy. (1982) (0)
- Therapeutic experience of the Italian Cooperative Group on ovarian carcinoma. (1991) (0)
- Transvaginal sonography, clor flow imaging and serum CA125 assay in the diagnosis of pelvic masses. (1993) (0)
- Perioperative Morbidity Following Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia in a Novel Italian Centre (2020) (0)
- Weekly epirubicin in gestational breast cancer (GBC) patients (pts) : a cooperative study group (2010) (0)
- Analysis of failures in patients with clinical stage I endometrial carcinoma treated with abdominal surgery and post-operative external pelvis irradiation (1992) (0)
- Clinical relevance of tumor angiogenesis in epithelial ovarian cancer (1999) (0)
- Contents Vol. 86, 2014 (2014) (0)
- Immunosuppressive acidic protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA125 and SCC. (1992) (0)
- Taxol (TAX) and ifosfamide (IFO) in advanced ovarian and breast cancer patients (pts): a phase I-II study (1996) (0)
- D-dimer in gynecological cancer (1989) (0)
- Cyfra 21-1 and SCC assay in squamous cell carcinoma of the uterine cervix: preliminary data. (1993) (0)
- The influence of anatomo-surgical stage, tumor size, histological type and lymph node status on the clinical outcome of patients with clinical FIGO stage IB-II cervical cancer. (1990) (0)
- CAM26, CAM29 and mucin-like carcinoma associated antigen in epithelial ovarian cancer. (1990) (0)
- Serum CA 125 in the management of ovarian cancer (1996) (0)
- [Methodological criteria in the diagnosis of benign and malignant pathology of the vulva]. (1987) (0)
- P53 overexpression in preneoplastic lesions and stage I carcinoma of endometrium (1995) (0)
- A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology. (1990) (0)
- CA125, CA19-9, CA15-3, CA72-4, TATI assays: useful biochemical tools in the assessment of disease status in patients with ovarian carcinoma (1989) (0)
- Cisplatin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: 12-year follow-up of a randomized trial (1995) (0)
- Uterine leiomyosarcoma: A clinical challenge for gynecologist and oncologist (2016) (0)
- Tumor markers for diagnosis and monitoring of malignant epithelial ovarian neoplasms. (1985) (0)
- Serum tumor markers in cervical cancer patients: biological and clinical relevance (1998) (0)
- The role of computerized tomography of the pelvis in the presurgical staging of carcinoma of the cervix and of the ovary. (1984) (0)
- Italian national multicentric study on post-menopausal pelvic masses (1993) (0)
- p53 status and response to paclitaxel-based chemotherapy in patients with advanced epithelial ovarian cancer. (1999) (0)
- Urinary epidermal growth factor (uEGF) in gynecologic malignancies (1991) (0)
- Intraperitoneal (ip) chemotherapy vs systemic (iv) chemotherapy in advanced ovarian cancer (AOC) pts with minimal residual disease (RD) after prior surgery: Preliminary results of a randomized study (1997) (0)
- Paclitaxel (TAX), carboplatin (CBDCA) and epidoxo¬rubicin (EPIDX) in advanced epithelial ovarian cancer (AEOC). (1999) (0)
- Preoperative serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55 kDa s-TNF-R and 75 kDa s-TNF-R), and soluble receptor of interleukin-6 in malignant and benign ovarian masses (1994) (0)
- CA 125, CA19-9, CA 15-3, CA 72-4, CA 50, TATI in ovarian carcinoma (1988) (0)
- The combined evaluation of several tumor-associated antigens in the differential diagnosis of ovarian masses (1990) (0)
- Screening for ovarian cancer in general population: a debated clinical challenge (2010) (0)
- [Preoperative plasma levels of von Willebrand factor in patients with cervical carcinoma]. (1988) (0)
- Serum levels of soluble interleukin-2 receptor in epithelial ovarian cancer (1992) (0)
- Treatment options in uterine leiomyosarcoma (2011) (0)
- P178 Carbon-Ion radiotherapy for malignant gynecological melanoma (2019) (0)
- Combination regimen including epirubicin, paclitaxel, and carboplatin in advanced epithelial ovarian cancer: Results from a phase II study (1999) (0)
- Ovarian Sertoli-Leyding cell tumors (OSLT). A retrospective MITO study (2011) (0)
- Clinical interpretation of laboratory data in the diagnostic evaluation of epithelial ovarian cancer (1992) (0)
- Immunosuppressive acidic protein (IAP) assayed with a turbidimetric immunoassay in patients with ovarian cancer (1990) (0)
- With Thanks to the International Journal of Gynecological Cancer: Reviewers of 2011 (2011) (0)
- p53 nuclear accumulation in adenomatous hyperplasia and stage I endometrioid carcinoma. (1997) (0)
- Serum levels of soluble interleukin-2 receptor in uterine malignancies. (1992) (0)
- [Analysis of failure of radical surgery in the treatment of invasive squamous cell carcinoma of the vulva]. (1988) (0)
- [Rational bases of surgery in the therapeutic strategy for ovarian cancer]. (1986) (0)
- Polycythemia due to erythropoietin secreting uterine leyomioma, case report (1998) (0)
- Positive p16 Immunostaining Is an Independent Prognostic Variable for Disease-free Survival and Overall Survival in Patients With Squamous Cell Carcinoma of the Vulva Treated With Radical Surgery and Inguinofemoral Lymphadenectomy: An Italian Single Center Retrospective Study (2023) (0)
- Progesterone and progestins: effects on breast cancer cells (2007) (0)
- Preoperative serum CA125, CA72-4, CA549 and immunosuppressive acidic protein in patients with epithelial ovarian cancer (1990) (0)
- “Neuroendocrine Tumor of the Uterine Cervix: A Therapeutic Challenge for Gynecologic Oncologists” (2017), by Angiolo Gadducci, Silvestro Carinelli, and (2022) (0)
- Cytokines in ovarian cancer (1996) (0)
- Fibrinopeptide A (FPA), d-dimer (DD), fibrinogen, von Willebrand factor (vWF), tissue type plasminogen activator (tPA) and plasminogen activator inhibitor (PAI) in patients with ovarian carcinoma. (1990) (0)
- P53 mutations and overexpression in ovarian carcers (1993) (0)
- P53 alterations in benign and malignant ovarian cancer (1993) (0)
- Localization and phototreatment of experimental and human gynecologic neoplasias by porphyrins and visible light (1983) (0)
- 224 Adjuvant chemotherapy in surgical stage I or II endometrioid endometrial cancer with myometrial invasion >50%: a multicenter retrospective study with long-term follow-up (2020) (0)
- Intraperitoneal vs systemic cisplatin in combination with systemic epidoxorubicin+ clophosphamide in advanced ovarian cancer patients with minimal residual disease after prior surgery: Update of a randomized study (1997) (0)
- Epidoxorubicin (EPI-DX) and lonidamine (LND) in refractory or recurrent epithelial ovarian cancer (EOC) (1994) (0)
- Management of non endometrioid ( Typ2) endometrial cancer: a multicenter Italian retrospective study. (2011) (0)
- Photodynamic therapy of gynecologic tumors by non coherent and laser light (1988) (0)
- A randomized trial of the North West Oncology Group (GONO) comparing intraperitoneal (ip) versus intravenous (iv) cisplatin (CDDP) in combimation with epidoxorubicin (epidox) and cyclophosphamide (CTX) in advanced ovarian carcinoma patients with residual disease <2cm after initial laparotomy (1997) (0)
- Obesity and Gynecologic cancer (2002) (0)
- [Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer]. (1986) (0)
- The Role of Endoscopy in Early Steage of Cervical Cancer: Robotic Versus Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy. Initial Experience (2008) (0)
- CA M29 : a new promising mucin-type tumor-associated antigen in patients with epithelial ovarian cancer (1990) (0)
- Clinical usefulness of the CAR-3 antigen in patients with pancreatic and ovarian carcinoma (1991) (0)
- [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects]. (1986) (0)
- Tumor markers in epithelial ovarian cancer: approaches to the clinical interpretation of laboratory data (1991) (0)
- [Cisplatin nephrotoxicity: effects on fractional excretion of sodium and enzymuria]. (1990) (0)
- Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes. (2023) (0)
- Hormone replacement therapy and breast and ovarian cancer (1997) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- Placental alkaline phosphatase (PLAP) , Mucin-like carcinoma-associated antigen (MCA) and CA 195 in ovarian carcinoma : comparison with CA125 (1989) (0)
- Fibrinopeptide-A (FPA), D-Dimer(DD) and Von Willebrandt Factor in patients with gynecological cancer (1990) (0)
- Role of anthracyclines in first line combination therapy: recent results of a meta-analysis of the EORTC (1991) (0)
- Serum intercellular adhesion molecule-1 (ICAM-1) assay in epithelial ovarian cancer. (1994) (0)
- Multivariate discriminant analysis of six tumor markers in the differential diagnosis of ovarian masses (1990) (0)
- 000441 MULTICENTER STUDY ON BORDERLINE OVARIAN TUMOR (2005) (0)
- [Plasma levels of von Willebrand factor in patients under integrated surgical-chemical therapy for ovarian cancer]. (1988) (0)
- Endometriosi: aspetti diagnostici e terapeutici (1984) (0)
- [Combined pharmacologic and surgical therapy of epithelial malignant neoplasms of the ovary in FIGO stages III-IV]. (1988) (0)
- Porphyrin-sensitized phototreatment as a conservative therapy in gynaecological oncology (1988) (0)
- Maternal glucose tolerance and fetal weight (1982) (0)
- Improved treatment with Gemzar for patients with ovarian cancer (1998) (0)
- Computerized tomography (CT) semeiotics in the presurgical evaluation of gynaecological neoplasias. (1985) (0)
- 512 Taxol (tax) and escalating doses of ifosfamide (IFO) in advanced breast and ovarian cancer patients (PTS) (1995) (0)
- Interferons and tumor necrosis factor in the treatment of ovarian carcinoma (1993) (0)
- Second-line chemotherapy in recurrent ovarian cancer (2002) (0)
- Radical vulvectomy in the treatment of invasive squamous vulvar cancer in Stage I-II FIGO at the Obstetric and Gynecologic Clinic of the University of Pisa. (1985) (0)
- EP696 Inoperable pelvic sidewall recurrence of gynecological cancer treated with proton and carbon ion radiotherapy: CNAO preliminary experience (2019) (0)
- The serum immunosuppressive acidic protein (IAP) assay in patients with uterine malignancies (1990) (0)
- Is reduction in size pathognomonic of functional ovarian cysts? (2003) (0)
- Nuclear accumulation of the p53 protein in endometrial adenocarcinoma (1993) (0)
- [Behavior of glycosylated hemoglobin in anomalies of glucose metabolism in pregnancy]. (1984) (0)
- Relationship between CA125, CA72-4 and CA15-3 serum levels before the 3rd and after the 6th course of chemotherapy and second look findings in patients with ovarian carcinoma. (1990) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Angiolo Gadducci?
Angiolo Gadducci is affiliated with the following schools:
